Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. Am Soc Clin Oncol Educ Book 2017;37:468-479
Date
06/01/2017Pubmed ID
28561719DOI
10.1200/EDBK_175712Scopus ID
2-s2.0-85041303313 (requires institutional sign-in at Scopus site) 12 CitationsAbstract
The prognosis of chronic phase chronic myeloid leukemia (CML) has improved so that life expectancy for patients responding to tyrosine kinase inhibitors (TKIs) is now equivalent to age-matched controls. Attention should be paid to comorbidities that impact survival. The success of TKI therapy can be easily and reliably assessed at well-accepted time points using quantitative polymerase chain reaction (PCR) standardized to the international scale. Patient-reported outcome (PRO) tools are readily available for use in the clinic and provide complementary information on the tolerance of TKIs. Effectively managing adverse events of TKIs can improve compliance and quality of life. Discontinuation of TKIs is the next frontier in CML. In select patients with sustained deep molecular remission, a discontinuation of TKI is associated with a durable treatment-free remission in approximately 50%. Patient engagement in their discontinuation can be achieved through a provider multi-team coaching, is complementary to the available guidelines, and may provide an additional safety net so that these discontinuations remain safe when applied in general practices.
Author List
Khoury HJ, Williams LA, Atallah E, Hehlmann RAuthor
Ehab L. Atallah MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antineoplastic AgentsDisease Management
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Medical Oncology
Prognosis
Protein Kinase Inhibitors
Remission Induction
Treatment Outcome
